|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2011-3-10
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Microalbuminuria is an early predictor of diabetic nephropathy and premature cardiovascular disease. We investigated whether treatment with an angiotensin-receptor blocker (ARB) would delay or prevent the occurrence of microalbuminuria in patients with type 2 diabetes and normoalbuminuria.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/21388309-21388316,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21388309-21451475,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21388309-21502981,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21388309-21519887,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21388309-21651398,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21388309-21651399,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21388309-21651400,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21388309-21651401,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21388309-21698568,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21388309-21767225,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21388309-22013597
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1533-4406
|
|
pubmed:author |
pubmed-author:HallerHermannH,
pubmed-author:ItoSadayoshiS,
pubmed-author:IzzoJoseph LJLJr,
pubmed-author:JanuszewiczAndrzejA,
pubmed-author:KatayamaShigehiroS,
pubmed-author:MenneJanJ,
pubmed-author:MimranAlbertA,
pubmed-author:ROADMAP Trial Investigators,
pubmed-author:RabelinkTon JTJ,
pubmed-author:RitzEberhardE,
pubmed-author:RuilopeLuis MLM,
pubmed-author:RumpLars CLC,
pubmed-author:VibertiGiancarloG
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
364
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
907-17
|
|
pubmed:dateRevised |
2011-10-21
|
|
pubmed:meshHeading |
pubmed-meshheading:21388309-Adolescent,
pubmed-meshheading:21388309-Adult,
pubmed-meshheading:21388309-Aged,
pubmed-meshheading:21388309-Albuminuria,
pubmed-meshheading:21388309-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:21388309-Blood Pressure,
pubmed-meshheading:21388309-Cardiovascular Diseases,
pubmed-meshheading:21388309-Coronary Disease,
pubmed-meshheading:21388309-Diabetes Mellitus, Type 2,
pubmed-meshheading:21388309-Double-Blind Method,
pubmed-meshheading:21388309-Female,
pubmed-meshheading:21388309-Follow-Up Studies,
pubmed-meshheading:21388309-Glomerular Filtration Rate,
pubmed-meshheading:21388309-Humans,
pubmed-meshheading:21388309-Imidazoles,
pubmed-meshheading:21388309-Male,
pubmed-meshheading:21388309-Middle Aged,
pubmed-meshheading:21388309-Tetrazoles,
pubmed-meshheading:21388309-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
|
|
pubmed:affiliation |
Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany. haller.hermann@mh-hannover.de
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
